A Study of LY3002813 in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ)

I5T-MC-AACG -

The purpose of this study is to evaluate the safety, tolerability and efficacy of LY3002813 in early symptomatic Alzheimer's disease.

Trial Summary

Age Range
60 - 85 years
Conditions the trial is for
Alzheimer's Disease
What the trial is testing?
Donanemab
Could I receive a Placebo?
Yes
Enrollment Goal
272
Trial Dates
Dec 18, 2017 - Sep 21, 2021
How long will I be in the trial?
Your participation could last up to 124 weeks and include up to 26 visits to the study center.
Trial Phase
II

Key Requirements

Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.

Participants Must:

  • Participant must have gradual and progressive change in memory for at least 6 months

  • Participant must be able to have a positron emission tomography (PET) scan

  • Participant must be able to have an magnetic resonance imaging (MRI) scan

  • Participant receiving treatment with one of the symptomatic Alzheimer's drugs must be on a stable dose for at least 2 months

  • Participant must have a reliable study partner with whom they live or have regular contact (at least 10 hours of communication each week), and who can come to study visits

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.